摘要
目的 评价晚期胰腺癌经动脉化疗或栓塞的临床效果。方法 36例胰腺癌患者分为两组 ,18例行动脉化疗或栓塞 (介入治疗 ) ,另 18例行全身化疗。结果 介入治疗组临床受益反应有效率为 5 5 .6 % (10 / 18) ,全身化疗组为 16 .7% (3/ 18) (P <0 .0 5 ) ,介入治疗组和全身化疗组 6个月、1年生存率和中位生存期分别为 35 %、11%、4.4个月和 30 %、8%、4.1个月 (P >0 .0 5 )。结论 胰腺癌的动脉化疗虽未能提高远期生存率 ,但能提高临床受益反应。
Objective To evaluate the clinical efficacy of transcatheter arterial infusion (TAI) or transcatheter arterial chemoembolization (TACE) in the treatment of advanced pancreatic cancer. Methods 36 cases of advanced pancreatic cancer were divided into two groups, 18 cases were treated with TAI or TACE(group A), other 18 cases were treated with systemic chemotherapy (group B). Results The clinical benefit response rate of the group A was 55.6%(10/18) and that of the group B was 16.7%(3/18), respectively( P <0.05). The 6 month, 1 year survival rates and median survival of group A were 35%, 11%, and 4.4 month, respectively; in the contrary, those of group B were 30%, 8%, 4.1 month, respectively ( P >0.05). Conclusions In the transcatheter arterial infusion group, no survival advantage could be demonstrated when compared with the controls, but TAI could effectively increase clinical benefit response and improve the quality of life of advanced pancreatic cancer.
出处
《介入放射学杂志》
CSCD
2001年第2期95-96,共2页
Journal of Interventional Radiology
